Maplight Therapeutics (NASDAQ:MPLT) Insider Erin Pennock Foff Sells 10,576 Shares

Key Points

• Erin Pennock Foff sold a total of 50,280 shares of Maplight over May 4–6 for about $1.43M, with the trades executed under a pre‑arranged Rule 10b5‑1 plan and leaving her with 374,549 shares (a 2.75% reduction).
• Maplight's stock climbed ~4% to $29.04 amid bullish analyst coverage (e.g., HC Wainwright's $45 target), but the company reported a notable Q1 EPS miss of -$2.47 versus -$1.05 and faces continued negative earnings and cash‑burn risk.

Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) insider Erin Pennock Foff sold 10,576 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $28.20, for a total transaction of $298,243.20. Following the transaction, the insider owned 374,549 shares of the company's stock, valued at $10,562,281.80. This trade represents a 2.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Erin Pennock Foff also recently made the following trade(s):

• On Wednesday, May 6th, Erin Pennock Foff sold 24,052 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.76, for a total transaction of $691,735.52.
• On Monday, May 4th, Erin Pennock Foff sold 15,652 shares of Maplight Therapeutics stock. The shares were sold at an average price of $27.96, for a total transaction of $437,629.92.

Maplight Therapeutics Stock Up 4.0%

Shares of NASDAQ:MPLT traded up $1.12 during trading on Wednesday, reaching $29.04. The company's stock had a trading volume of 267,979 shares, compared to its average volume of 342,018. The stock has a market cap of $1.24 billion and a PE ratio of -0.73. Maplight Therapeutics, Inc. has a 12 month low of $12.24 and a 12 month high of $33.28. The company's 50 day moving average price is $22.60.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($1.42). On average, equities analysts predict that Maplight Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Maplight Therapeutics

Large investors have recently bought and sold shares of the business. MetLife Investment Management LLC purchased a new position in Maplight Therapeutics during the 4th quarter valued at $172,000. New York State Common Retirement Fund purchased a new position in Maplight Therapeutics during the 4th quarter valued at $93,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Maplight Therapeutics during the 4th quarter valued at $70,000. Bank of New York Mellon Corp boosted its holdings in Maplight Therapeutics by 10.1% during the 1st quarter. Bank of New York Mellon Corp now owns 39,465 shares of the company's stock valued at $802,000 after acquiring an additional 3,608 shares during the period. Finally, 5AM Venture Management LLC purchased a new position in Maplight Therapeutics during the 4th quarter valued at $16,687,000.

Trending Headlines about Maplight Therapeutics

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its "Buy" rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a "Buy" rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright's detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on MPLT. Wall Street Zen cut Maplight Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 21st. Canaccord Genuity Group began coverage on Maplight Therapeutics in a report on Thursday, March 19th. They issued a "buy" rating and a $35.00 target price for the company. HC Wainwright began coverage on Maplight Therapeutics in a report on Monday. They issued a "buy" rating and a $45.00 target price for the company. Weiss Ratings began coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They issued a "sell (e)" rating for the company. Finally, Needham & Company LLC began coverage on Maplight Therapeutics in a report on Wednesday, April 8th. They issued a "buy" rating and a $37.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $34.43.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.